These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11189688)

  • 21. Building Successful Relationships in the PLCO Cancer Screening Trial.
    Marcus PM; Broski KG; Buys SS; Childs J; Church TR; Gohagan JK; Gren LH; Higgins D; Jaggi R; Jenkins V; Johnson CC; Lappe K; O'Brien B; Ogden SL; Prorok PC; Reding D; Shambaugh V; Yokochi LA; Yurgalevitch S
    Rev Recent Clin Trials; 2015; 10(3):181-6. PubMed ID: 26238208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data Processing and Analytic Support in the PLCO Cancer Screening Trial.
    Mabie J; Riley T; Marcus PM; Black A; Rozjabek H; Yu K; Young M; Austin J; Rathmell J; Williams C; Prorok PC
    Rev Recent Clin Trials; 2015; 10(3):233-7. PubMed ID: 26238116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.
    Lacey JV; Kreimer AR; Buys SS; Marcus PM; Chang SC; Leitzmann MF; Hoover RN; Prorok PC; Berg CD; Hartge P;
    BMC Cancer; 2009 Mar; 9():84. PubMed ID: 19292893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Grubb RL; Pinsky P; Prorok PC; Andriole GL
    Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Ford ME; Havstad SL; Davis SD
    Clin Trials; 2004; 1(4):343-51. PubMed ID: 16279272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
    Gohagan JK; Prorok PC; Kramer BS; Cornett JE
    J Urol; 1994 Nov; 152(5 Pt 2):1905-9. PubMed ID: 7523735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.
    Black A; Huang WY; Wright P; Riley T; Mabie J; Mathew S; Ragard L; Hermansen S; Yu K; Pinsky P; Prorok PC; Freedman ND; Hoover RN
    Rev Recent Clin Trials; 2015; 10(3):238-45. PubMed ID: 26435289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center.
    Gren LH; Lamerato LE; Wright P; Marcus PM
    Rev Recent Clin Trials; 2015; 10(3):194-9. PubMed ID: 26238206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Doria-Rose VP; Laiyemo AO; Church T; Yokochi LA; Yurgalevitch S; Rathmell J; Andriole GL; Buys S; Crawford ED; Fouad M; Isaacs C; Lamerato L; Reding D; Prorok PC; Berg CD;
    J Natl Cancer Inst; 2012 Feb; 104(4):280-9. PubMed ID: 22298838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.
    Zhu CS; Pinsky PF; Kramer BS; Prorok PC; Purdue MP; Berg CD; Gohagan JK
    J Natl Cancer Inst; 2013 Nov; 105(22):1684-93. PubMed ID: 24115361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The National Cancer Institute Multi-Screening Trial.
    Prorok P
    Can J Oncol; 1994 Nov; 4 Suppl 1():98-9; discussion 100-1. PubMed ID: 8853500
    [No Abstract]   [Full Text] [Related]  

  • 35. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
    Kramer BS; Gohagan J; Prorok PC; Smart C
    Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen Resource.
    Carrick DM; Black A; Gohagan JK; Khan A; Pettit K; Williams C; Yu K; Yurgalevitch S; Huang WY; Zhu C
    Rev Recent Clin Trials; 2015; 10(3):212-22. PubMed ID: 26238117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial.
    Bazzi L; Lamerato LE; Varner J; Shambaugh VL; Cordes JE; Ragard LR; Marcus PM
    Rev Recent Clin Trials; 2015; 10(3):200-5. PubMed ID: 26238207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Taylor KL; Shelby R; Gelmann E; McGuire C
    J Natl Cancer Inst; 2004 Jul; 96(14):1083-94. PubMed ID: 15265970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.
    Sharma A; Hostetter J; Morrison J; Wang K; Siegel E
    J Digit Imaging; 2016 Apr; 29(2):160-4. PubMed ID: 26385814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.